AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhengliqi mixture (FLM) 60 mL twice a day
Number of subjects: 560
Study 23596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Dachangshu (BL 25), and Zhigou (TE 6) twice a day
Number of subjects: 560
Study 23596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with FLM and acupuncture
Number of subjects: 560
Study 23596812 — intervention group
Group type: COMPARATOR
Intervention: Mosapride (5 mg thrice a day) and Macrogol 4000 (10 g twice a day)
Number of subjects: 560
Study 21660772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intervention session to teach empirically valid self‐directed weight‐control methods
Number of subjects: 66
Study 21660772 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only control condition
Number of subjects: 66
Study 21660772 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-weighing frequency
Number of subjects: 66
Study 19349340 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based rehabilitation therapy for five months
Number of subjects: 737
Study 19349340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional rehabilitation therapy)
Number of subjects: 737
Study 16193299 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA)
Number of subjects: 110
Study 16193299 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg of oral calcium daily (groups IB, IIB, IIIB)
Number of subjects: 110
Study 15130257 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline therapy (100 mg)
Number of subjects: 91
Study 15130257 — intervention group
Group type: COMPARATOR
Intervention: Inpatient and outpatient treatment groups
Number of subjects: 91
Study 11524318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 11524318 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) Propofol
Number of subjects: 0
Study 11524318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol Bolus followed by Isoflurane
Number of subjects: 0
Study 9239772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 295
Study 9239772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV)
Number of subjects: 295
Study 9239772 — intervention group
Group type: EXPERIMENTAL
Intervention: COMVAX (Hib and hepatitis B vaccine)
Number of subjects: 295
Study 8512675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing using the Schwade Arm Ergometer Protocol
Number of subjects: 64
Study 8512675 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of achieved values with baseline (pre-exercise) values
Number of subjects: 64
Study 2962417 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐DSG
Number of subjects: 60
Study 2962417 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐GSD
Number of subjects: 60
Study 2962417 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐LNG
Number of subjects: 60
Study 29692602 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) alone
Number of subjects: 24
Study 29692602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) alone
Number of subjects: 24
Study 29692602 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) plus Ezetimibe (10 mg)
Number of subjects: 24
Study 29692602 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 28715142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg, 3 times/day)
Number of subjects: 17
Study 28715142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25240140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 341
Study 25240140 — intervention group
Group type: COMPARATOR
Intervention: Short Psychodynamic Supportive Psychotherapy (SPSP)
Number of subjects: 341
Study 22899814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic NaHCO3 ingestion (ALK)
Number of subjects: 12
Study 22899814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 21995692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 153
Study 21995692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 153
Study 21995692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe 10/10 mg
Number of subjects: 153
Study 21995692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study 18466210 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 38
Study 18466210 — intervention group
Group type: COMPARATOR
Intervention: Four daily insulin injections
Number of subjects: 38
Study 17144454 — intervention group
Group type: EXPERIMENTAL
Intervention: PYM emulsion applied 3 times daily on the lesions
Number of subjects: 30
Study 17144454 — intervention group
Group type: COMPARATOR
Intervention: Control group with only matrix applied
Number of subjects: 30
Study 12725542 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (OD) gentamicin 5 mg kg(‐1) d(‐1)
Number of subjects: 172
Study 12725542 — intervention group
Group type: COMPARATOR
Intervention: Conventional 8-hourly dosing (TDS) gentamicin 6 mg kg(‐1) d(‐1)
Number of subjects: 172
Study 10697444 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy based programme for therapeutic outcomes monitoring
Number of subjects: 500
Study 9109868 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI of the forearm in IBM patients
Number of subjects: 30
Study 1585841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 273
Study 1585841 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no nicotine gum)
Number of subjects: 273
Study 3995516 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg ISDSR
Number of subjects: 20
Study 3995516 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 40 mg ISDSR (at 07.30 and 13.30 h)
Number of subjects: 20
Study 3995516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31250602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure therapy (20 minutes, 5 times per week for 4 weeks)
Number of subjects: 14
Study 31250602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recovery intervention)
Number of subjects: 14
Study 29700480 — intervention group
Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 528
Study 29700480 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic group
Number of subjects: 528
Study 26808136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg or 100 mg daily)
Number of subjects: 2173
Study 26808136 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2173
Study 24471665 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHDF with catheter tip at right atrium
Number of subjects: 94
Study 24471665 — intervention group
Group type: COMPARATOR
Intervention: CVVHDF with catheter tip at superior vena cava
Number of subjects: 94
Study 22742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotic therapy with fosfomycin-trometamol 1x3g
Number of subjects: 494
Study 22742538 — intervention group
Group type: COMPARATOR
Intervention: Initial symptomatic treatment with ibuprofen 3x400mg for 3 days
Number of subjects: 494
Study 21063142 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intraoperative hydration (no more than 1500 ml in the first 2 hours)
Number of subjects: 15
Study 21063142 — intervention group
Group type: COMPARATOR
Intervention: No hydration intervention (control group)
Number of subjects: 15
Study 17560512 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F FDG PET
Number of subjects: 0
Study 17560512 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel imaging techniques
Number of subjects: 0
Study 17560512 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances in molecular imaging
Number of subjects: 0
Study 16279901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with lamivudine 100 mg per day for 52 weeks and IFN 5 MIU per day for 16 weeks after the first 8 weeks (group A)
Number of subjects: 75
Study 16279901 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy 100 mg per day for 52 weeks (group B)
Number of subjects: 75
Study 16885196 — intervention group
Group type: COMPARATOR
Intervention: TNFA (‐308 G>A) polymorphism
Number of subjects: 305
Study 16885196 — intervention group
Group type: COMPARATOR
Intervention: IFNGR2 Ex7‐128 C>T polymorphism
Number of subjects: 305
Study 16885196 — intervention group
Group type: COMPARATOR
Intervention: Combination of IFNGR2 Ex7‐128 C/C and TNFA ‐308 A/A genotypes
Number of subjects: 305
Study 16885196 — intervention group
Group type: COMPARATOR
Intervention: IL1A (‐889 C>T) and IL12A variants
Number of subjects: 305
Study 11236850 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 88
Study 11236850 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 88
Study 11236850 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3 and EQ-5D
Number of subjects: 88
Study 8867523 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadoline
Number of subjects: 0
Study 8867523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8867523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen-codeine combination
Number of subjects: 0
Study 1507326 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric extracorporeal shock wave lithotripsy (ESWL) retreatment
Number of subjects: 50
Study 1507326 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 50
Study 6388070 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-T3 antibody (5 mg i.v./day for 14 days)
Number of subjects: 18
Study 6388070 — intervention group
Group type: COMPARATOR
Intervention: steroid treatment
Number of subjects: 18
Study 6388070 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-T3 antibody
Number of subjects: 18
Study 29595751 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information provided at the invitation for routine screening
Number of subjects: 1060
Study 29595751 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information provided after detection of cellular abnormalities
Number of subjects: 1060
Study 29595751 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information provided for recommended precancer treatment
Number of subjects: 1060
Study 29595751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 1060
Study 30281402 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving motivational advice to younger students
Number of subjects: 2274
Study 30281402 — intervention group
Group type: COMPARATOR
Intervention: Receiving motivational advice from expert teachers
Number of subjects: 2274
Study 30281402 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving advice
Number of subjects: 2274
Study 30281402 — intervention group
Group type: COMPARATOR
Intervention: Receiving expert advice
Number of subjects: 2274
Study 27075143 — intervention group
Group type: EXPERIMENTAL
Intervention: Music via speakers
Number of subjects: 30
Study 27075143 — intervention group
Group type: EXPERIMENTAL
Intervention: Music via headphones
Number of subjects: 30
Study 27075143 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 30
Study 27075143 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between speakers and headphones
Number of subjects: 30
Study 27075143 — intervention group
Group type: COMPARATOR
Intervention: Initial assignment of speakers
Number of subjects: 30
Study 27075143 — intervention group
Group type: COMPARATOR
Intervention: Initial assignment of headphones
Number of subjects: 30
Study 24707787 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-driven regulation of study effort
Number of subjects: 0
Study 24707787 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven regulation of study effort
Number of subjects: 0
Study 24707787 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of study time interpretation
Number of subjects: 0
Study 22167563 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (subcutaneous, dose range 0.2‐10 µg/kg)
Number of subjects: 52
Study 20427630 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 606
Study 20427630 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 606
Study 17905315 — intervention group
Group type: EXPERIMENTAL
Intervention: Office chair with a motor‐driven seat performing a horizontal rotary movement
Number of subjects: 280
Study 17905315 — intervention group
Group type: COMPARATOR
Intervention: Chair of the same design without the rotary seat movement
Number of subjects: 280
Study 15691277 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG induction therapy
Number of subjects: 84
Study 12019929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to reduce sodium intake for 2 weeks
Number of subjects: 82
Study 10721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg thrice a day for three days, starting one hour prior to angiography)
Number of subjects: 71
Study 10721643 — intervention group
Group type: COMPARATOR
Intervention: Control (routine angiography without captopril)
Number of subjects: 71
Study 10721643 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg thrice a day for three days)
Number of subjects: 71
Study 7537489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 142
Study 7537489 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 142
Study 31045329 — intervention group
Group type: EXPERIMENTAL
Intervention: WinFood Classic (WFC)
Number of subjects: 499
Study 31045329 — intervention group
Group type: EXPERIMENTAL
Intervention: WinFood Lite (WFL)
Number of subjects: 499
Study 31045329 — intervention group
Group type: COMPARATOR
Intervention: Fortified corn-soy blend plus (CSB+)
Number of subjects: 499
Study 28451442 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 0
Study 28451442 — intervention group
Group type: COMPARATOR
Intervention: Single steroid injection (followed by later surgery if required)
Number of subjects: 0
Study 24958769 — intervention group
Group type: EXPERIMENTAL
Intervention: RESPOND intervention
Number of subjects: 528
Study 24958769 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 528
Study 23324512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (complete medication history, limited physical examination, provision of guideline-concordant recommendations, and 1-year follow-up)
Number of subjects: 136
Study 23324512 — intervention group
Group type: COMPARATOR
Intervention: Usual care without pharmacist interactions (Control)
Number of subjects: 136
Study 23324512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 136
Study 21401833 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 0
Study 21401833 — intervention group
Group type: COMPARATOR
Intervention: Placebo/active comparator
Number of subjects: 0
Study 18381837 — intervention group
Group type: EXPERIMENTAL
Intervention: BE-ACTIV intervention
Number of subjects: 20
Study 18381837 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 20
Study 16096994 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder (PD) diagnosis based on DSM-IV criteria
Number of subjects: 3004
Study 16096994 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold panic disorder
Number of subjects: 3004
Study 16096994 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews for epidemiological surveys
Number of subjects: 3004
Study 12880499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120
Study 12880499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 120
Study 12880499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sertraline and CBT
Number of subjects: 120
Study 12880499 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 120
Study 10642897 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation (one tablet daily for 10 weeks)
Number of subjects: 0
Study 10642897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study 8895156 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐3 fatty acids (fish oil) 8 g for 16 weeks
Number of subjects: 100
Study 8895156 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 100
Study 1856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 5
Study 1856908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6828277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (2-g dose administered intravenously)
Number of subjects: 71
Study 6828277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to ampicillin)
Number of subjects: 71
Study 30121944 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) treatment for 3 weeks during neonatal care
Number of subjects: 34
Study 30121944 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 34
Study 30293225 — intervention group
Group type: EXPERIMENTAL
Intervention: Long CCI (≥ 1.75 mm)
Number of subjects: 128
Study 30293225 — intervention group
Group type: COMPARATOR
Intervention: Short CCI (< 1.75 mm)
Number of subjects: 128
Study 27306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum and pemetrexed) in combination with erlotinib
Number of subjects: 3
Study 27306517 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKIs
Number of subjects: 3
Study 25207513 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 404
Study 25207513 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring weight
Number of subjects: 404
Study 25207513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym attendance/participating in exercise classes
Number of subjects: 404
Study 25207513 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating less fat
Number of subjects: 404
Study 22947843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation (n=10)
Number of subjects: 30
Study 22947843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation (n=10)
Number of subjects: 30
Study 22947843 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group, n=10)
Number of subjects: 30
Study 21050497 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 hour face-to-face educational intervention
Number of subjects: 31
Study 21050497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 18787352 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (DOC)
Number of subjects: 122
Study 18787352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vinorelbine (VIN)
Number of subjects: 122
Study 18787352 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover treatment (X-DOC)
Number of subjects: 122
Study 18787352 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover treatment (X-VIN)
Number of subjects: 122
Study 16004670 — intervention group
Group type: EXPERIMENTAL
Intervention: CC plus HS (Clomiphene Citrate plus Hormone Supplementation)
Number of subjects: 71
Study 16004670 — intervention group
Group type: COMPARATOR
Intervention: No HS (Clomiphene Citrate alone)
Number of subjects: 71
Study 12445222 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage procedure (n = 20)
Number of subjects: 40
Study 12445222 — intervention group
Group type: COMPARATOR
Intervention: Two-stage procedure (n = 20)
Number of subjects: 40
Study 10522715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping (LM) with blue dye plus radiocolloid
Number of subjects: 1135
Study 10522715 — intervention group
Group type: COMPARATOR
Intervention: Lymphatic mapping (LM) with blue dye alone
Number of subjects: 1135
Study 10522715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node (SN) identification in MSLT group after learning phase
Number of subjects: 1135
Study 10522715 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of nodal metastases in MSLT group
Number of subjects: 1135
Study 7795283 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily, every other day)
Number of subjects: 140
Study 7795283 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (weekend regimen)
Number of subjects: 140
Study 7795283 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (every other day)
Number of subjects: 140
Study 7795283 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg nocte)
Number of subjects: 140
Study 2201794 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical low dose heparin (0.125 gm./l., 25,000 units per l.)
Number of subjects: 70
Study 2201794 — intervention group
Group type: COMPARATOR
Intervention: Glycine solution alone (control)
Number of subjects: 70
Study 7299385 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 39
Study 7299385 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg/kg
Number of subjects: 39
Study 7299385 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 39
Study 31130666 — intervention group
Group type: EXPERIMENTAL
Intervention: KP extract 90 mg/day
Number of subjects: 0
Study 31130666 — intervention group
Group type: EXPERIMENTAL
Intervention: KP extract 180 mg/day
Number of subjects: 0
Study 31130666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29482225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (shared decision support intervention)
Number of subjects: 248